Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

Abstract Purpose Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers. Methods We retrospectively reviewed records from virtual MTBs held between 04/2020–03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions. Results During 25 meetings, 32 presenters discussed 44 cases. Approximately half ( n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% ( n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% ( n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% ( n = 13), enrollment in the observational NCI Natural History Study to 21% ( n = 9), neuropathology review and molecular testing at the NIH to 17% ( n = 7), and all received management suggestions. Conclusion Virtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.